Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 108 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma... September 22, 2025 Couple Married For 48 Years Shared A Touching Moment As They... August 22, 2019 The Obesity Paradox: It Increases Diabetes Risk But Can Help Cancer... March 13, 2020 Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant... March 8, 2023 Load more HOT NEWS Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of... A Subset of Patients with NSCLC Respond Poorly to the COVID-19... Some Women Avoid Breast Cancer Screening After False-Positive Mammogram Results EMA Recommends Granting a Conditional Marketing Authorisation for Selinexor
